Health Economics Policy and Law最新文献

Incremental choices, system-wide impact on health system performance. 增量选择，对卫生系统绩效的全系统影响。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-10-23 DOI: 10.1017/S174413312510025X

Rocco Friebel, Iris Wallenburg

引用次数: 0

The contaminated blood scandal in England: exploring the social harms experienced by infected and affected individuals. 英国受污染的血液丑闻：探索受感染和受影响的个人所经历的社会危害。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-08-19 DOI: 10.1017/S1744133125100200

Emily Warren, Eva Cyhlarova, Jessica Carlisle, Martin Knapp, Ellen Nolte

{"title":"The contaminated blood scandal in England: exploring the social harms experienced by infected and affected individuals.","authors":"Emily Warren, Eva Cyhlarova, Jessica Carlisle, Martin Knapp, Ellen Nolte","doi":"10.1017/S1744133125100200","DOIUrl":"10.1017/S1744133125100200","url":null,"abstract":"During the 1970s and 1980s, over 30,000 people in the UK were infected with HIV and/or hepatitis C because of treatment with blood and blood products for conditions such as haemophilia or through blood transfusion. We used the social harms perspective to understand the experiences of those affected. We conducted in-depth interviews with 41 infected people and 11 family members and analysed the data according to five dimensions of social harm: physical harms, psychological harms, cultural harms, economic harms, and harms of misrecognition. We found that people were harmed by the medical system, the social context that perpetuated stigma and shame against them, and successive governments being largely unwilling to address the many health, social, and economic impacts of infection on families. What stood out were the many reports of harms of misrecognition, which were often experienced as more irreconcilable than the circumstances of infection itself. They were also harms that have been largely ignored.While patient safety encompasses a broad field of work, much of the research focuses on physical harm and medical error. The social harms lens can provide important insights into patient safety incidents as it can help explain the complexity of the different dimensions of harm that individuals and their families experience.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-16"},"PeriodicalIF":3.3,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling Medicaid fraud and abuse: the influence of price transparency and state political context. 揭露医疗补助欺诈和滥用：价格透明度和国家政治背景的影响。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-24 DOI: 10.1017/S1744133125100157

Ahreum Han, Christian L Janousek, Shihyun Noh

引用次数: 0

The roadmaps to managed competition: theory and practice. 管理竞争的路线图：理论与实践。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-23 DOI: 10.1017/S1744133125100170

Josefa Henriquez, Shuli Brammli-Greenberg, Maria Trottmann, Francesco Paolucci

引用次数: 0

Making care primary: a renewed investment into primary care. 初级保健：重新对初级保健进行投资。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-15 DOI: 10.1017/S174413312510011X

Cameron J Sabet, Bhav Jain, Sandeep Palakodeti

{"title":"Making care primary: a renewed investment into primary care.","authors":"Cameron J Sabet, Bhav Jain, Sandeep Palakodeti","doi":"10.1017/S174413312510011X","DOIUrl":"https://doi.org/10.1017/S174413312510011X","url":null,"abstract":"The Making Care Primary (MCP) model represents a sharp shift in Medicare's approach to primary care, yet its current design risks duplicating failures from prior alternative payment models. Our editorial suggests refinements to address these gaps. To prevent early provider dropout from MCP's rigid track-based system, we propose a sliding-scale infrastructure payment model that adjusts based on practice needs rather than abrupt phase-outs. Given MCP's reliance on community-based organisations (CBOs) for social determinants of health interventions, we also advocate for direct, outcomes-based contracts between providers and CBOs, ensuring accountability for patient outcomes rather than passive referrals. We recommend that MCP enforce data-sharing mandates for commercial insurers and Medicaid agencies, drawing from Washington State's successful Multi-Payer Collaborative, to avoid payer disengagement that plagued previous multi-payer models. To expand beyond conventional quality measures, we propose integrating patient-centred outcomes from the International Consortium for Health Outcomes Measurement, making sure MCP captures meaningful clinical impact. Finally, we propose programme adjustments frequently at two- to three-year intervals to refine risk adjustment methodologies. These approaches could enhance MCP's sustainability, preventing the financial instability and misaligned incentives that undermined past value-based care initiatives.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lead-attributable productivity losses in low- and middle-income countries. 铅在低收入和中等收入国家造成的生产力损失。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-03 DOI: 10.1017/S1744133125100121

Bret Ericson, Mary Jean Brown

{"title":"Lead-attributable productivity losses in low- and middle-income countries.","authors":"Bret Ericson, Mary Jean Brown","doi":"10.1017/S1744133125100121","DOIUrl":"https://doi.org/10.1017/S1744133125100121","url":null,"abstract":"This study estimates productivity losses resulting from intellectual decrement due to paediatric lead exposure in low- and middle-income countries (LMICs). The published literature on blood lead levels in LMICs was reviewed and summarised. Intelligence Quotient decrement and consequent productivity losses were calculated for a one-year cohort of 5-year-old children in each country. We calculated the present value of lifetime earnings as the discounted average earning potential for workers in a specific economy. Blood lead level (BLL) data for children were available for 39 countries and could be interpolated for additional 82 countries, resulting in 121 countries in the final analysis. Total lead-attributable productivity losses in LMICs ranged from USD 305 billion in our high discount scenario to USD 499 billion in our low discount scenario for each one-year cohort of 5-year-old children (2019 USD). As a share of GDP, these costs ranged from 0.7 to 4.2% by region, depending on discount scenario used. Total economic impacts were generally consistent with previous estimates and further validate those efforts with a substantially expanded dataset. Differences in the findings resulted primarily from the use of a more conservative dose-response model in the present study. Improved reporting of BLLs is essential and could be facilitated through a centralised registry of study results.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement. 探索经济评价在西班牙的报告定位药品为公共报销。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 DOI: 10.1017/S1744133124000264

Laura Vallejo-Torres, Juan Oliva-Moreno, Félix Lobo

{"title":"Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement.","authors":"Laura Vallejo-Torres, Juan Oliva-Moreno, Félix Lobo","doi":"10.1017/S1744133124000264","DOIUrl":"10.1017/S1744133124000264","url":null,"abstract":"Therapeutic positioning reports (IPTs, Spanish acronym) are a crucial tool for informing funding and pricing decisions for drugs in the Spanish healthcare system. In 2020, for the first time the inclusion of economic evaluations (EEs) was explicitly set as a primary objective in a new Action Plan aimed at consolidating IPTs. This paper seeks to examine the uptake of EE into IPTs and to compare the methods and techniques employed in the EEs conducted during the two-year pilot phase following the reform, i.e., from June 2021 to July 2023. During this period, a total of 181 IPTs were published, with 19 (10.5%) incorporating an EE section. However, out of these 19 identified IPTs, six did not actually conduct a de novo EE, and four only performed a drug cost minimisation analysis. Six IPTs conducted EE analyses following international methodological standards. Based on this review, we observe that the percentage of IPTs incorporating EEs had remained low and exhibited significant heterogeneity. The experience of these two years must be translated into lessons that can serve to reinforce the evaluation of the efficiency of medicines in Spain in the coming years.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"233-245"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How should medicines reimbursement work? The views of Spanish experts. 药品报销应如何进行？西班牙专家的观点。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 DOI: 10.1017/S174413312400029X

Juan Carlos Rejon-Parrilla, David Epstein, Daniel Pérez-Troncoso, Jaime Espin

引用次数: 0

Advancing healthcare decision-making for the common good: a tribute to Professor Rovira Forns. 为共同利益推进医疗保健决策：向罗维拉·福恩斯教授致敬。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 Epub Date: 2025-09-11 DOI: 10.1017/S1744133125100194

Joan Costa-Font, Rosa Rodriguez-Monguio

引用次数: 0

Has regional decentralisation saved lives during the COVID-19 pandemic? 在COVID-19大流行期间，区域分散是否挽救了生命？